Vericel Corporation VCEL
Set alert
At close · Oct 30
After hours · Oct 30, 7:30 PM ET
- YTD
- +11.80%
- 1 year
- +16.59%
- Open
- 43.02
- Prev close
- 42.91
- Mkt cap
- 2.06B
- Vol
- 598.74K
- Avg vol
- 512.19K
- EPS
- 0.47
- P/E
- 85.66
- Div yield
- 0.00%
More statistics
- Low
- 40.01
- High
- 43.02
- Forward P/E
- 47.56
- Beta
- 1.02
- Short ratio
- 9.42
- Inst. own
- 110.21%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 40.62
- 200-d avg
- 38.64
- 1y target
- 59.71
5D chart
Signals (83)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 29, 3:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:50 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:50 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 28, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:45 PM | 3 days ago |
| RSI: Oversold | Oct 28, 3:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:40 PM | 3 days ago |
| RSI: Oversold | Oct 28, 2:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:00 PM | 3 days ago |
| RSI: Oversold | Oct 28, 1:00 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 3 days ago |
| RSI: Oversold | Oct 28, 12:10 PM | 3 days ago |
| RSI: Oversold | Oct 28, 11:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:10 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:00 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:40 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:00 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 3 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 3 days ago |
| RSI: Oversold | Oct 27, 3:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 9:35 AM | 4 days ago |
| RSI: Oversold | Oct 26, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:50 PM | 5 days ago |
| RSI: Overbought | Oct 26, 1:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:05 PM | 5 days ago |
| RSI: Overbought | Oct 26, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 10:55 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:40 AM | 5 days ago |
News
1 week ago globenewswire.com
Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026
BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the…
-
2 weeks ago benzinga.com
Truist Securities Maintains Buy on Vericel, Lowers Price Target to $52
Truist Securities analyst Richard Newitter maintains Vericel (NASDAQ:VCEL) with a Buy and lowers the price target from $58 to $52.
1 month ago seekingalpha.com
Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago seekingalpha.com
Vericel: MACI And Regenerative Knee Cartilage
Vericel's MACI already has an established commercial base, which I think gives them an easier path for future growth. MACI's arthroscopic delivery could also help it expand among surgeons. That's why…
1 month ago globenewswire.com
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026
BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the…
1 month ago defenseworld.net
Canada Pension Plan Investment Board Takes Position in Vericel Corporation $VCEL
Canada Pension Plan Investment Board purchased a new position in Vericel Corporation (NASDAQ: VCEL) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund…
2 months ago defenseworld.net
Vericel Corporation $VCEL Shares Purchased by Bank of America Corp DE
Bank of America Corp DE boosted its holdings in Vericel Corporation (NASDAQ: VCEL) by 19.7% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned…
-
3 months ago benzinga.com
TD Cowen Maintains Buy on Vericel, Raises Price Target to $58
TD Cowen analyst Joshua Jennings maintains Vericel (NASDAQ:VCEL) with a Buy and raises the price target from $55 to $58.
-
3 months ago benzinga.com
Truist Securities Reiterates Buy on Vericel, Raises Price Target to $58
Truist Securities analyst Richard Newitter reiterates Vericel (NASDAQ:VCEL) with a Buy and raises the price target from $54 to $58.
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Vericel, Raises Price Target to $72
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Vericel (NASDAQ:VCEL) with a Buy and raises the price target from $70 to $72.
3 months ago marketbeat.com
Vericel Q2 Earnings Call Highlights
Vericel NASDAQ: VCEL reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with…
3 months ago seekingalpha.com
Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript
Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript
3 months ago zacks.com
Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates
Vericel Corporation (VCEL) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.01 per share a year…
-
3 months ago benzinga.com
Vericel Q2 EPS $0.04 Beats $(0.03) Estimate, Sales $77.457M Beat $72.689M Estimate
Vericel (NASDAQ:VCEL) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.03) by 233.33 percent. This is a 500 percent increase over losses of $(0.01) per…
-
3 months ago benzinga.com
Vericel Raises FY2026 Sales Guidance from $326.000M-$336.000M to $330.000M-$340.000M vs $332.199M Est
Vericel (NASDAQ:VCEL) raises FY2026 sales outlook from $326.000 million-$336.000 million to $330.000 million-$340.000 million vs $332.199 million estimate.
3 months ago globenewswire.com
Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340…
-
3 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Vericel, Maintains $70 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Vericel (NASDAQ:VCEL) with a Buy and maintains $70 price target.
3 months ago defenseworld.net
Vericel Corporation $VCEL Shares Sold by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC trimmed its position in Vericel Corporation (NASDAQ: VCEL) by 3.1% during the first quarter, according to its most recent filing with the Securities and…
-
3 months ago benzinga.com
Truist Securities Maintains Buy on Vericel, Raises Price Target to $54
Truist Securities analyst Richard Newitter maintains Vericel (NASDAQ:VCEL) with a Buy and raises the price target from $42 to $54.
3 months ago globenewswire.com
Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
BURLINGTON, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the…
4 months ago fool.com
Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests
10,000 Common Stock shares were sold for a transaction value of $402,000 at an average price of around $40.24 per share on June 18, 2026. The sale represented 38% of Halpin's direct Common Stock…
4 months ago globenewswire.com
Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the…
5 months ago fool.com
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.
5 months ago marketbeat.com
Vericel Q1 Earnings Call Highlights
Vericel NASDAQ: VCEL reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as…
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Vericel, Raises Price Target to $70
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Vericel (NASDAQ:VCEL) with a Buy and raises the price target from $64 to $70.
5 months ago seekingalpha.com
Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
5 months ago zacks.com
Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates
Vericel Corporation (VCEL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.
-
5 months ago benzinga.com
Vericel Raises FY2026 Sales Guidance from $316.000M-$326.000M to $326.000M-$336.000M vs $323.377M Est
Vericel (NASDAQ:VCEL) raises FY2026 sales outlook from $316.000 million-$326.000 million to $326.000 million-$336.000 million vs $323.377 million estimate.
-
5 months ago benzinga.com
Vericel Q1 EPS $(0.12) Beats $(0.15) Estimate, Sales $68.425M Beat $63.638M Estimate
Vericel (NASDAQ:VCEL) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 47.83 percent increase over losses of $(0.23) per…
5 months ago globenewswire.com
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91%
6 months ago zacks.com
Wall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 53.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the…
-
6 months ago benzinga.com
Truist Securities Maintains Buy on Vericel, Lowers Price Target to $42
Truist Securities analyst Richard Newitter maintains Vericel (NASDAQ:VCEL) with a Buy and lowers the price target from $48 to $42.
-
7 months ago benzinga.com
Vericel Corp. Awarded $196.8M HHS BARDA Contract For NonSurgical Debridement, Research And Development In Biotechnology (Except Nanobiotechnology)
https://sam.gov/opp/f339ca12b7e047cdac559fe926d1a190/view
-
8 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Vericel, Raises Price Target to $64
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Vericel (NASDAQ:VCEL) with a Buy and raises the price target from $60 to $64.
-
8 months ago benzinga.com
Vericel Sees FY2026 Sales $316.000M-$326.000M vs $325.310M Est
2026 Financial GuidanceTotal revenue of $316 to $326 millionMACI revenue of $280 to $286 millionGross margin of approximately 75%Adjusted EBITDA margin of approximately 27%
-
8 months ago benzinga.com
Vericel Q4 EPS $0.45 Beats $0.39 Estimate, Sales $92.918M Beat $91.122M Estimate
Vericel (NASDAQ:VCEL) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.39 by 15.38 percent. This is a 18.42 percent increase over earnings of $0.38 per…
8 months ago benzinga.com
Earnings Scheduled For February 26, 2026
Earnings Scheduled For February 26, 2026
9 months ago benzinga.com
Why Is Vericel Stock Gaining Tuesday?
Vericel Corporation (NASDAQ: VCEL) stock rose on Tuesday after announcing preliminary financial results for 2025.
-
10 months ago benzinga.com
Truist Securities Maintains Buy on Vericel, Lowers Price Target to $45
Truist Securities analyst Richard Newitter maintains Vericel (NASDAQ:VCEL) with a Buy and lowers the price target from $50 to $45.
-
11 months ago benzinga.com
Truist Securities Reiterates Buy on Vericel, Raises Price Target to $50
Truist Securities analyst Richard Newitter reiterates Vericel (NASDAQ:VCEL) with a Buy and raises the price target from $41 to $50.
11 months ago benzinga.com
Earnings Scheduled For November 6, 2025
Earnings Scheduled For November 6, 2025
-
1 year ago benzinga.com
Truist Securities Maintains Buy on Vericel, Lowers Price Target to $41
Truist Securities analyst Richard Newitter maintains Vericel (NASDAQ:VCEL) with a Buy and lowers the price target from $46 to $41.
1 year ago benzinga.com
This FedEx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
This FedEx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
-
1 year ago benzinga.com
Canaccord Genuity Maintains Buy on Vericel, Lowers Price Target to $58
Canaccord Genuity analyst Caitlin Cronin maintains Vericel (NASDAQ:VCEL) with a Buy and lowers the price target from $61 to $58.
-
1 year ago benzinga.com
Vericel Reaffirms Full-year 2025 Profitability Guidance Of Gross Margin Of 74% And Adjusted EBITDA Margin Of 26%
2025 Financial GuidanceReaffirmed MACI full-year revenue growth in the low 20% rangeUpdated Burn Care revenue guidance for the second half of 2025 to be in line with recent run rate of approximately…
-
1 year ago benzinga.com
Stephens & Co. Reiterates Overweight on Vericel, Maintains $67 Price Target
Stephens & Co. analyst Mason Carrico reiterates Vericel (NASDAQ:VCEL) with a Overweight and maintains $67 price target.
-
1 year ago benzinga.com
What Analysts Are Saying About Vericel Stock
What Analysts Are Saying About Vericel Stock
-
1 year ago benzinga.com
Stephens & Co. Reiterates Overweight on Vericel, Maintains $67 Price Target
Stephens & Co. analyst Mason Carrico reiterates Vericel (NASDAQ:VCEL) with a Overweight and maintains $67 price target.